Combined hormone therapy at menopause and breast cancer: A warning - short-term use increases risk

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5116-5119

  Bernstein, Leslie ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; EDITORIAL; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; MENOPAUSE; PRIORITY JOURNAL; SHORT COURSE THERAPY; BREAST TUMOR; FEMALE; NOTE; PRACTICE GUIDELINE; RISK FACTOR;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; GUIDELINES AS TOPIC; HUMANS; MENOPAUSE; RISK FACTORS;

EID: 70449726859     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.9988     Document Type: Editorial

References (43)

1. Lee S, Ross RK, Pike MC: An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049-2058, 2005
2. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
3. U.S. Food and Drug Administration: Draft Guidance for Industry on Labeling for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Prescribing Information for Health Care Providers and Patient Labeling; Availability. http://www.fda.gov/OHRMS/DOCKETS/98fr/98d-0834-nad0004.pdf
4. Practice Committee of the American Society for Reproductive Medicine: Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 90:S88-S102, 2008 (suppl 3)
5. North American Menopause Society: Estrogen and progestogen use in periand postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 14:168-182, 2007
6. AACE Menopause Guidelines Revision Task Force: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 12:315-337, 2006
7. U.S. Preventive Services Task Force: Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 142:855-860, 2005
8. North American Menopause Society: Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 11:589-600, 2004
9. North American Menopause Society: Amended report from the NAMS advisory panel on postmenopausal hormone therapy. Menopause 10:6-12, 2003
10. North American Menopause Society: Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause 10:49-506, 2003
11. Ravdin PM, Cronin KA, Howlader N, et al: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674, 2007
12. Robbins AS, Clarke CA: Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25:3437-3439, 2007
13. Glass AG, Lacey JV Jr, Carreon D, et al: Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:1152-1161, 2007
14. Clarke CA, Glaser SL, Uratsu SL, et al: Recent declines in hormone therapy utilization and breast cancer incidence: Clinical and population-based evidence. J Clin Oncol 24:e49-e50, 2006
15. Horner MJ, Ries LAG, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, National Cancer Institute, 2009
16. Glass A, Hoover RN: Changing incidence of breast cancer. J Natl Cancer Inst 80:1076-1077, 1988
17. Pfeiffer RM, Mitani A, Matsuno RK, et al: Racial differences in breast cancer trends in the United States (2000-2004). J Natl Cancer Inst 100:751-752, 2008
18. Hausauer AK, Keegan TH, Chang ET, et al: Recent trends in breast cancer incidence in US white women by urban/rural and poverty status. BMC Med. http://www.biomedcentral.com/1741-7015/7/31
19. Chlebowski RT, Kuller LH, Prentice RL, et al: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573-587, 2009
20. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 289:3243-3253, 2003
21. Hing E, Brett KM: Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 108:33-40, 2006
22. Hersh AL, Stefanick ML, Stafford RS: National use of menopausal hormone therapy: Annual trends and response to recent evidence. JAMA 291:47-53, 2004
23. Haas JS, Kaplan CP, Gerstenberger EP, et al: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140:184-188, 2004
24. Anderson GL, Chlebowski RT, Rossouw JE, et al: Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55:103-115, 2006
25. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
26. Fournier A, Berrino F, Clavel Chapelon F: Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 107:103-111, 2008
27. Hulley S, Furberg C, Barrett-Connor E, et al: Noncardiovascular disease outcomes during 6.8 Years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 288:58-64, 2002
28. Tannen RL, Weiner MG, Xie D, et al: Perspectives on hormone replacement therapy: The Women's Health Initiative and new observational studies sampling the overall population. Fertil Steril 90:258-264, 2008
29. Speroff L: The future of postmenopausal hormone therapy: It's time to move forward. Maturitas 57:103-106, 2007
30. Phillips LS, Langer RD: Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis. Fertil Steril 83:558-566, 2005
31. Prentice RL, Manson JE, Langer RD, et al: Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170:12-23, 2009
32. Banks E, Canfell K: Invited commentary: Hormone therapy risks and benefits - The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 170:24-28, 2009
33. Prentice RL, Chlebowski RT, Stefanick ML, et al: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167:1207-1216, 2008
34. Fournier A, Mesrine S, Boutron-Ruault M-C, et al: Estrogen-progestagen menopausal hormone therapy and breast cancer: Does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27:5138-5143, 2009
35. Power ML, Anderson BL, Schulkin J: Attitudes of obstetrician- gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause 16:500-508, 2009
36. Power ML, Schulkin J, Rossouw JE: Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists. Menopause 14:20-28, 2007
37. Brett AS, Carney PI, McKeown RE: Brief report: Attitudes toward hormone therapy after the Women's Health Initiative: A comparison of internists and gynecologists. J Gen Intern Med 20:416-418, 2005
38. Bluming AZ, Tavris C: Hormone replacement therapy: Real concerns and false alarms. Cancer J 15:93-104, 2009
39. Speroff L: Postmenopausal hormone therapy and the risk of breast cancer: A contrary thought. Menopause 15:393-400, 2008
40. Wingert P, Kantrowitz B: Uh, O! Why medical experts were shocked by Oprah Winfrey's take on hormone replacement and Suzanne Somers's controversial theories on aging. Newsweek, http://www.newsweek.com/id/200025
41. Wingert P, Kantrowitz B: Are bio-identical hormones safe? Why the FDA is cracking down on these 'natural' menopausal therapies. Newsweek, Feb 7, 2008, http://www.newsweek.com/id/108727
42. Sommers S: Health and hormones. http://www.suzannesomers.com/ HealthAndHormones/Default.aspx
43. US Food and Drug Administration: Compounded menopause hormone therapy drugs. January 09, 2008 News Release. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110239.htm